Copland, Mhairi and Ariti, Cono and Thomas, Ian F. and Upton, Laura and Sydenham, Mia and Mehta, Priyanka and Islam, Shahid and Kjeldsen, Lars and Burnett, Alan K. and Hills, Robert K. and Russell, Nigel and Dennis, Mike (2024) A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial. British Journal of Haematology, 204 (3). ISSN 0007-1048

<img xmlns="http://www.w3.org/1999/xhtml" src="https://pub.demo35.eprints-hosting.org/348/5.haslightboxThumbnailVersion/309444.pdf" class="document_preview_tile_thumbnail"/> <span xmlns="http://www.w3.org/1999/xhtml" title="309444.pdf">309444.pdf</span>
309444.pdf - Published Version
Available under License Creative Commons Attribution.

Download (512kB)
Abstract

Improving outcomes for older patients with acute myeloid leukaemia remains an unmet need. As part of the LI-1 trial, we evaluated lenalidomide (LEN), in combination with low-dose cytosine arabinoside (LDAC) in patients aged &gt;60 years unfit for intensive therapy and compared this to LDAC alone. 202 patients randomised 1:1 were evaluable. Overall response rate (CR+CRi) was higher for LDAC+LEN versus LDAC (26% and 13.7%, respectively, P=0.031). However, there was no difference in overall survival between the arms (14% and 11.5% at 2 years for LDAC+LEN and LDAC, respectively). Addition of LEN was associated with increased toxicity and supportive care requirements.

Information
Title A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial
Creators Copland, Mhairi and Ariti, Cono and Thomas, Ian F. and Upton, Laura and Sydenham, Mia and Mehta, Priyanka and Islam, Shahid and Kjeldsen, Lars and Burnett, Alan K. and Hills, Robert K. and Russell, Nigel and Dennis, Mike
Identification Number 10.1111/bjh.19220
Date March 2024
Divisions College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Publisher Wiley
Additional Information Funding: We are grateful to the NIHR for supporting local trial delivery, Blood Cancer UK for research support, the Haematology Clinical Trials Unit and Centre for Trials Research, Cardiff University for managing the trial and Celgene for providing drug and additional support for this Investigator Initiated Trial.
Library
URI https://pub.demo35.eprints-hosting.org/id/eprint/348
Item Type Article
Depositing User Unnamed user with email ejo1f20@soton.ac.uk
Date Deposited 11 Jun 2025 16:37
Revision 36
Last Modified 12 Jun 2025 10:10
View Item